{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:10:48Z","timestamp":1793661048310,"version":"4.5.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002857","name":"China Pharmaceutical University","doi-asserted-by":"publisher","award":["CPU2018GF02"],"award-info":[{"award-number":["CPU2018GF02"]}],"id":[{"id":"10.13039\/501100002857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ejmech.2023.115370","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T11:17:20Z","timestamp":1681298240000},"page":"115370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Discovery of Thieno[3,2-d]pyrimidine derivatives as potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) kinase"],"prefix":"10.1016","volume":"255","author":[{"given":"Yunxin","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haodong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8746-3363","authenticated-orcid":false,"given":"Lili","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yerong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2189-9356","authenticated-orcid":false,"given":"Yadong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115370_bib1","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115370_bib2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA damage response in cancer","volume":"60","author":"O'Connor","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2023.115370_bib3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2015.2","article-title":"DNA damage and the balance between survival and death in cancer biology","volume":"16","author":"Roos","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2023.115370_bib4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","article-title":"The DNA damage response: making it safe to play with knives","volume":"40","author":"Ciccia","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2023.115370_bib5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Pili\u00e9","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115370_bib6","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2023.115370_bib7","doi-asserted-by":"crossref","first-page":"873","DOI":"10.4155\/fmc.15.33","article-title":"Progress in the development of specific inhibitors for the treatment of cancer","volume":"7","author":"Foote","year":"2015","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115370_bib8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13045-019-0733-6","article-title":"Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand","volume":"12","author":"Mei","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2023.115370_bib9","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41568-018-0034-3","article-title":"Targeting ATR in cancer","volume":"18","author":"Emilio","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2023.115370_bib10","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.currproblcancer.2017.05.002","article-title":"Targeting ATR in cancer medicine","volume":"41","author":"Sundar","year":"2017","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.ejmech.2023.115370_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114109","article-title":"Recent advances in DDR (DNA damage response) inhibitors for cancer therapy","volume":"230","author":"Cheng","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115370_bib12","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/1541-7786.MCR-14-0240","article-title":"A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function","volume":"13","author":"Menezes","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115370_bib13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3390\/cancers10080275","article-title":"The impact of p53 dysfunction in ATR inhibitor cytotoxicity and chemo- and radiosensitisation","volume":"10","author":"Middleton","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2023.115370_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13837","article-title":"ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A","volume":"7","author":"Williamson","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115370_bib15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/cr.2011.128","article-title":"The MRE11 GAR motif regulates DNA double-strand break processing and ATR activation","volume":"22","author":"Yu","year":"2012","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2023.115370_bib16","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","article-title":"ATM mutations in cancer: therapeutic implications","volume":"15","author":"Choi","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2023.115370_bib17","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1535-7163.MCT-16-0378","article-title":"AZD6738, A novel oral inhibitor of ATR, induces synthetic lethality with ATM deficiency in gastric cancer cells","volume":"16","author":"Min","year":"2017","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2023.115370_bib18","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1200\/JCO.2017.72.3502","article-title":"Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma","volume":"35","author":"Shindo","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115370_bib19","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3390\/ijms23010523","article-title":"ATM: functions of ATM kinase and its relevance to hereditary tumors","volume":"23","author":"Ueno","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115370_bib20","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","article-title":"ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells","volume":"127","author":"Kwok","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2023.115370_bib21","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115370_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107450","article-title":"Targeting ATR as Cancer Therapy: a new era for synthetic lethality and synergistic combinations?","volume":"207","author":"Bradbury","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2023.115370_bib23","doi-asserted-by":"crossref","first-page":"14151","DOI":"10.1021\/acs.jmedchem.0c00766","article-title":"Synthetic lethality through the lens of medicinal chemistry","volume":"63","author":"Myers","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115370_bib24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115370_bib25","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1158\/0008-5472.CAN-16-3398","article-title":"ATM deficiency is associated with sensitivity to PARP1- and ATR inhibitors in lung adenocarcinoma","volume":"77","author":"Schmitt","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115370_bib26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","article-title":"The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage inducing or repair\u2013compromising therapies in preclinical cancer models","volume":"19","author":"Wengner","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2023.115370_bib27","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1535-7163.MCT-21-0615","article-title":"RP-3500: a novel, potent, and selective ATR inhibitor that is effective in preclinical models as a monotherapy and in combination with PARP inhibitors","volume":"21","author":"Roulston","year":"2022","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2023.115370_bib28","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1017\/erm.2014.10","article-title":"Chemical strategies for development of ATR inhibitors","volume":"16","author":"Llona-Minguez","year":"2014","journal-title":"Expet Rev. Mol. Med."},{"key":"10.1016\/j.ejmech.2023.115370_bib29","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/13543776.2022.2027911","article-title":"Discovery of small-molecule ATR inhibitors for potential cancer treatment: a patent review from 2014 to present","volume":"32","author":"Hu","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2023.115370_bib30","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1021\/jm101488z","article-title":"Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and rad3 related (ATR) protein kinase as potential anticancer agents","volume":"54","author":"Charrier","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115370_bib31","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1021\/acs.jmedchem.9b00426","volume":"62","author":"Knegtel","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115370_bib32","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1021\/jm301859s","article-title":"Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity","volume":"56","author":"Foote","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115370_bib33","doi-asserted-by":"crossref","first-page":"9889","DOI":"10.1021\/acs.jmedchem.8b01187","article-title":"Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and rad3 related (ATR) kinase with application as an anticancer agent","volume":"61","author":"Foote","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115370_bib34","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1021\/acs.jmedchem.0c00369","article-title":"Damage incorporated: discovery of the potent, highly selective, orally available ATR inhibitor BAY 1895344 with favorable pharmacokinetic properties and promising efficacy in monotherapy and in combination treatments in preclinical tumor models","volume":"63","author":"L\u00fccking","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115370_bib35","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1535-7163.MCT-20-1026","article-title":"Novel and highly potent ATR inhibitor M4344 kills cancer cells with replication stress, and enhances the chemotherapeutic activity of widely used DNA damaging agents","volume":"20","author":"Jo","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2023.115370_bib36","doi-asserted-by":"crossref","first-page":"TPS3153","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS3153","article-title":"A first-in-human phase I study of ATR inhibitor M1774 in patients with solid tumors","volume":"39","author":"Yap","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115370_bib37","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-human trial of the oral ataxia telangiectasia and rad3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2023.115370_bib38","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.bmcl.2017.01.045","article-title":"Discovery of pyrazolopyrimidine derivatives as novel inhibitors of ataxia telangiectasia and rad3 related protein (ATR)","volume":"27","author":"Ramachandran","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115370_bib39","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1021\/ml500352s","article-title":"Structure-based drug design of novel, potent, and selective azabenzimidazoles (ABI) as ATR inhibitors","volume":"6","author":"Barsanti","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115370_bib40","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1021\/ml500353p","article-title":"Structure-based drug design of novel potent and selective tetrahydropyrazolo[1,5-a]pyrazines as ATR inhibitors","volume":"6","author":"Barsanti","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115370_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128651","article-title":"Discovery of 6,7-dihydro-5H-pyrrolo[3,4-d] pyrimidine derivatives as a new class of ATR inhibitors","volume":"63","author":"Chen","year":"2022","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115370_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114187","article-title":"Discovery of a potent and highly selective inhibitor of ataxia telangiectasia mutated and rad3-related (ATR) kinase: structural activity relationship and antitumor activity both in vitro and in vivo","volume":"232","author":"Bin","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115370_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114945","article-title":"Discovery of novel 7,7-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidines as ATR inhibitors based on structure-based drug design","volume":"246","author":"Qi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115370_bib44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1021\/jm501026z","article-title":"Phosphatidylinositol 3-kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring","volume":"58","author":"Andrs","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115370_bib45","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1021\/jm800295d","article-title":"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer","volume":"51","author":"Folkes","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115370_bib46","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.jmb.2017.04.006","article-title":"Rationally designed PI3K\u03b1 mutants to mimic ATR and their use to understand binding specificity of ATR inhibitors","volume":"429","author":"Lu","year":"2017","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2023.115370_bib47","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1021\/acs.jmedchem.6b00306","article-title":"Discovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinase","volume":"59","author":"Huang","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115370_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113963","article-title":"Dual target inhibitors based on EGFR: promising anticancer agents for the treatment of cancers (2017-)","volume":"227","author":"Hu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115370_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111884","article-title":"Recent advance in the development of novel, selective and potent FGFR inhibitors","volume":"186","author":"Liu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115370_bib50","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1021\/acs.jmedchem.2c00030","article-title":"Medicinal chemistry strategies for the development of Bruton's tyrosine kinase inhibitors against resistance","volume":"65","author":"Sun","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115370_bib51","doi-asserted-by":"crossref","first-page":"12403","DOI":"10.1021\/acs.jmedchem.0c00696","article-title":"Small-molecule fms-like tyrosine kinase 3 inhibitors: an attractive and efficient method for the treatment of acute myeloid leukemia","volume":"63","author":"Zhong","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115370_bib52","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1021\/acs.jmedchem.8b01092","article-title":"Insights into current tropomyosin receptor kinase (TRK) inhibitors: development and clinical application","volume":"62","author":"Yan","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115370_bib53","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd.2018.21","article-title":"Kinase inhibitors: the road ahead","volume":"17","author":"Ferguson","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115370_bib54","doi-asserted-by":"crossref","first-page":"8249","DOI":"10.1021\/jm500973a","article-title":"Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor","volume":"57","author":"Finlay","year":"2014","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423003367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423003367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:53:23Z","timestamp":1759330403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423003367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":54,"alternative-id":["S0223523423003367"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115370","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of Thieno[3,2-d]pyrimidine derivatives as potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) kinase","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115370","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115370"}}